Abstract
HMPL-689, a novel class I PI3Kδ inhibitor, has shown tolerable safety profile and encouraging preliminary efficacy in patients (pts) with relapsed/refractory (R/R) lymphoma in the dose-escalation stage of a phase I study (NCT03128164) in China (Junning C, et al, ASH 2020). Here we present the preliminary safety and efficacy results of the study evaluating HMPL-689 at recommended phase 2 dose (RP2D) of 30mg QD as a monotherapy in pts with R/R lymphomas.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
